Targeted therapy method for membranous nephropathy

Abstract

The invention discloses a targeted therapy method for membranous nephropathy, and relates to the technical field of a method of treating membranous nephropathy. The targeted therapy method comprises the following steps: by using nano particles of amphiphilic macromolecules as a drug carrier, packaging glucocorticoid and an immunosuppressive agent in a hydrophobic core to guarantee medicine molecule structures in the particles to be integrated; protecting the surface by hydrophilic layers of the nano particles; coupling anti-glomerular basement membrane antibodies on the surfaces of the particles, directly combining the antibodies with glomerular basement membrane antigens exposed after the glomerular basement membrane is damaged to seal protein leakage; conveying medicines to the glomerular basement membrane to combine with the glomerular basement membrane antigens, and releasing the glucocorticoid or the immunosuppressive agent packaged in the nano sustained release particles. The targeted therapy method has the beneficial effects that: the nano particles formed by amphiphilic macromolecules are used as the carrier so as to couple with anti-glomerular basement membrane antibodies, so that the targeted therapy method has the characteristics of being lasting, orientating and locating, quick in effect-taking, efficient and stable.

Description

technical field [0001] The invention relates to the technical field of methods for treating membranous nephropathy, in particular to a method for targeted treatment of membranous nephropathy. Background technique [0002] Membranous nephropathy (MN) is one of the most common pathological types of nephrotic syndrome in adults, accounting for about 13.5% of primary glomerular diseases, and the incidence rate is increasing year by year. 80% of patients present with nephrotic syndrome (NS), and 30%-40% of patients have microscopic hematuria. This disease is very prone to embolism complications, and the incidence of renal vein thrombosis can be as high as 40%-50%, which is an important factor for poor prognosis. Most patients have normal renal function at the onset of the disease, but 4%-8% of patients have intractable ascites, refractory hypertension and renal insufficiency, and even need hemodialysis, which greatly affects the physical and mental health of patients. And incre...

AI Technical Summary

Problems solved by technology

However, the MN disease itself mainly affects the kidneys, and systemic medication can cause systemic side effects; secondly, high-dose, long-term use of glucocorticoids and immunosuppressants will also bring many complications to patients, seriously affecting the quality of life of patients , such as peptic ulcer bleeding, inducing or exacerbating infection, iatrogenic adrenal hyperfunction, inducing hypertension and arteriosclerosis, osteoporosis, muscle atrophy, slow wound healing, secondary diabetes, bone marrow suppression, gonadal suppression, severe impairment of liver and kidney function

Moreover, the blood concentration of oral administration fluctuates greatly, and the curative effect is not stable

In addition, even with active treatment, there are still nearly half of MN patients with insignificant curative effect, manifested as persistent NS, and about 15%-30% of patients will experience one or more recurrences

Images